{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T08:30:26Z","timestamp":1765269026071,"version":"3.40.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00520-025-09346-4","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T03:13:04Z","timestamp":1741835584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of triplet antiemetic prophylaxis against chemotherapy-induced nausea and vomiting in patients with soft tissue sarcomas receiving consecutive-day doxorubicin and ifosfamide therapy"],"prefix":"10.1007","volume":"33","author":[{"given":"Yunami","family":"Yamada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihito","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Tsugita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"issue":"1","key":"9346_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/2045-3329-2-14","volume":"2","author":"Z Burningham","year":"2012","unstructured":"Burningham Z, Hashibe M, Spector L et al (2012) The epidemiology of sarcoma. Clin Sarcoma Res 2(1):14","journal-title":"Clin Sarcoma Res"},{"issue":"6","key":"9346_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1200\/JCO.23.01275","volume":"42","author":"AR Weiss","year":"2024","unstructured":"Weiss AR, Harrison DJ (2024) Soft tissue sarcomas in adolescents and young adults. J Clin Oncol 42(6):675\u2013685","journal-title":"J Clin Oncol"},{"issue":"4","key":"9346_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1634\/theoncologist.7-4-348","volume":"7","author":"AI Spira","year":"2002","unstructured":"Spira AI, Ettinger DS (2002) The use of chemotherapy in soft-tissue sarcomas. Oncologist 7(4):348\u2013359","journal-title":"Oncologist"},{"key":"9346_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13569-019-0115-4","volume":"9","author":"B Kasper","year":"2019","unstructured":"Kasper B (2019) The challenge of finding new therapeutic avenues in soft tissue sarcomas. Clin Sarcoma Res 9:5","journal-title":"Clin Sarcoma Res"},{"issue":"12","key":"9346_CR5","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1007\/s00520-012-1448-1","volume":"20","author":"P Fern\u00e1ndez-Ortega","year":"2012","unstructured":"Fern\u00e1ndez-Ortega P, Caloto MT, Chirveches E et al (2012) Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients\u2019 quality of life. Support Care Cancer 20(12):3141\u20133148","journal-title":"Support Care Cancer"},{"issue":"5","key":"9346_CR6","doi-asserted-by":"publisher","first-page":"601","DOI":"10.6004\/jnccn.2009.0040","volume":"7","author":"SM Grunberg","year":"2009","unstructured":"Grunberg SM (2009) Obstacles to the implementation of antiemetic guidelines. J Natl Compr Canc Netw 7(5):601\u2013605","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"9346_CR7","first-page":"555","volume":"45","author":"K Tanaka","year":"2015","unstructured":"Tanaka K, Mizusawa J, Fukuda H et al (2015) Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304). Jpn J Clin Oncol 45(6):555\u2013561","journal-title":"Jpn J Clin Oncol"},{"issue":"24","key":"9346_CR8","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2020) Antiemetics: ASCO Guideline Update. J Clin Oncol 38(24):2782\u20132797","journal-title":"J Clin Oncol"},{"key":"9346_CR9","unstructured":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Antiemesis Version 1. 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf Accessed 1 July 2024."},{"issue":"1","key":"9346_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00520-023-08220-5","volume":"32","author":"K Jordan","year":"2023","unstructured":"Jordan K, Chan A, Gralla RJ et al (2023) Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC\/ESMO consensus recommendation. Support Care Cancer 32(1):53","journal-title":"Support Care Cancer"},{"issue":"7","key":"9346_CR11","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10147-024-02535-x","volume":"29","author":"H Iihara","year":"2024","unstructured":"Iihara H, Abe M, Wada M et al (2024) 2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis. Int J Clin Oncol 29(7):873\u2013888","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"9346_CR12","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","volume":"21","author":"RM Navari","year":"2013","unstructured":"Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21(6):1655\u20131663","journal-title":"Support Care Cancer"},{"issue":"1","key":"9346_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00520-023-08224-1","volume":"32","author":"BL Rapoport","year":"2023","unstructured":"Rapoport BL, Herrstedt J, Snow RC et al (2023) 2023 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 32(1):36","journal-title":"Support Care Cancer"},{"issue":"49","key":"9346_CR14","doi-asserted-by":"publisher","first-page":"e5460","DOI":"10.1097\/MD.0000000000005460","volume":"95","author":"H Kusaba","year":"2016","unstructured":"Kusaba H, Kumagai H, Inadomi K et al (2016) Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy. Medicine (Baltimore) 95(49):e5460","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"9346_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10147-015-0908-2","volume":"21","author":"H Iihara","year":"2016","unstructured":"Iihara H, Fujii H, Yoshimi C et al (2016) Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy. Int J Clin Oncol 21(2):409\u2013418","journal-title":"Int J Clin Oncol"},{"key":"9346_CR16","doi-asserted-by":"crossref","unstructured":"Iihara H, Ishihara M, Fujii H et al (2016) Comparison of the control of nausea and vomiting among several moderately emetic-risk chemotherapy regimens. J Cancer 18;7(5):569\u201375","DOI":"10.7150\/jca.13637"},{"issue":"1","key":"9346_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-015-0852-1","volume":"21","author":"H Takeuchi","year":"2016","unstructured":"Takeuchi H, Saeki T, Aiba K et al (2016) Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary. Int J Clin Oncol 21(1):1\u201312","journal-title":"Int J Clin Oncol"},{"key":"9346_CR18","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. Available online: https:\/\/www.eortc.be\/services\/doc\/ctc\/ Accessed 19 Sep 2022."},{"key":"9346_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ejphar.2013.10.015","volume":"722","author":"D Warr","year":"2014","unstructured":"Warr D (2014) Prognostic factors for chemotherapy induced nausea and vomiting. Eur J Pharmacol 722:192\u2013196","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"9346_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/jjco\/hyaa231","volume":"51","author":"K Tanaka","year":"2021","unstructured":"Tanaka K, Ozaki T (2021) Adjuvant and neoadjuvant chemotherapy for soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. Jpn J Clin Oncol 51(2):180\u2013184","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"9346_CR21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375(2):134\u2013142","journal-title":"N Engl J Med"},{"issue":"3","key":"9346_CR22","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jpainsymman.2013.05.003","volume":"47","author":"N Mizukami","year":"2014","unstructured":"Mizukami N, Yamauchi M, Koike K et al (2014) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manage 47(3):542\u2013550","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"9346_CR23","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00520-015-2829-z","volume":"24","author":"M Abe","year":"2016","unstructured":"Abe M, Hirashima Y, Kasamatsu Y et al (2016) Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Support Care Cancer 24(2):675\u2013682","journal-title":"Support Care Cancer"},{"issue":"9","key":"9346_CR24","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/jjco\/hyx084","volume":"47","author":"K Nakashima","year":"2017","unstructured":"Nakashima K, Murakami H, Yokoyama K et al (2017) A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy. Jpn J Clin Oncol 47(9):840\u2013843","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"9346_CR25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","volume":"23","author":"T Yanai","year":"2018","unstructured":"Yanai T, Iwasa S, Hashimoto H et al (2018) A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol 23(2):382\u2013388","journal-title":"Int J Clin Oncol"},{"issue":"14","key":"9346_CR26","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.22.01997","volume":"41","author":"L Sandhya","year":"2023","unstructured":"Sandhya L, Devi Sreenivasan N, Goenka L et al (2023) Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer. J Clin Oncol 41(14):2617\u20132627","journal-title":"J Clin Oncol"},{"key":"9346_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fnut.2017.00070","volume":"4","author":"Y Hori","year":"2018","unstructured":"Hori Y, Sakamoto A, Goto T et al (2018) Analysis of dietary intake during consecutive-day chemotherapy for bone and soft-tissue sarcomas. Front Nutr 4:70","journal-title":"Front Nutr"},{"key":"9346_CR28","first-page":"6650915","volume":"1","author":"B Shahrami","year":"2023","unstructured":"Shahrami B, Biglari M, Kaveh-Ahangaran R et al (2023) (2023) Pharmacotherapy considerations in antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. Eur J Cancer Care (Engl) 1:6650915","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"10","key":"9346_CR29","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1111\/bcp.13322","volume":"83","author":"P Patel","year":"2017","unstructured":"Patel P, Leeder JS, Piquette-Miller M et al (2017) Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 83(10):2148\u20132162","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"9346_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4103\/jpp.JPP_182_16","volume":"8","author":"PS Kataria","year":"2017","unstructured":"Kataria PS, Kendre PP, Patel AA (2017) Ifosfamide-induced encephalopathy precipitated by aprepitant: a rarely manifested side effect of drug interaction. J Pharmacol Pharmacother 8(1):38\u201340","journal-title":"J Pharmacol Pharmacother"},{"issue":"1","key":"9346_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10637-017-0487-3","volume":"36","author":"S Bun","year":"2018","unstructured":"Bun S, Yonemori K, Akagi T et al (2018) Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy. Invest New Drugs 36(1):151\u2013155","journal-title":"Invest New Drugs"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09346-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09346-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09346-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T07:09:51Z","timestamp":1745305791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09346-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["9346"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09346-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H Iihara has received honoraria for lectures from Taiho Pharm., Chugai Pharma., Yakult Honsha., Astellas Pharma., Eli Lilly and Company., Daiichi Sankyo., AstraZeneca plc, Nippon Kayaku, Ono Pharm., and Nippon Boehringer Ingelheim; and consulting fees from Pfizer Eisai and Taiho Pharm. H Fujii has received honoraria for lectures from Ono Pharm., Chugai Pharm., and Taiho Pharm.   A Suzuki has received honoraria for lectures from Toa Eiyo, Asahi Kasei Pharma, Daiichi Sankyo, Pfizer Eisai, Nippon Shinyaku, Celltrion Healthcare Japan, Otsuka Pharm., Sandoz, Tsumura, Nipro, Taiho Pharm., Kyowa Kirin, Nippon Chemiphar, Japan Blood Products Organization, Takeda Pharm., and Nippon Boehringer Ingelheim; and grants made to institution from Nippon Kayaku, Asahi Kasei Pharma, Chugai Pharm., Taiho Pharm., Daiichi Sankyo, Japan Blood Products Organization, Mochida Pharm., Sun Pharma; and consulting fees from Nippon Kayaku.  The other authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"274"}}